Successful Treatment of Molybdenum Cofactor Deficiency Type A With cPMP
- 1 May 2010
- journal article
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 125 (5), e1249-e1254
- https://doi.org/10.1542/peds.2009-2192
Abstract
Molybdenum cofactor deficiency (MoCD) is a rare metabolic disorder characterized by severe and rapidly progressive neurologic damage caused by the functional loss of sulfite oxidase, 1 of 4 molybdenum-dependent enzymes. To date, no effective therapy is available for MoCD, and death in early infancy has been the usual outcome. We report here the case of a patient who was diagnosed with MoCD at the age of 6 days. Substitution therapy with purified cyclic pyranopterin monophosphate (cPMP) was started on day 36 by daily intravenous administration of 80 to 160 μg of cPMP/kg of body weight. Within 1 to 2 weeks, all urinary markers of sulfite oxidase (sulfite, S-sulfocysteine, thiosulfate) and xanthine oxidase deficiency (xanthine, uric acid) returned to almost normal readings and stayed constant (>450 days of treatment). Clinically, the infant became more alert, convulsions and twitching disappeared within the first 2 weeks, and an electroencephalogram showed the return of rhythmic elements and markedly reduced epileptiform discharges. Substitution of cPMP represents the first causative therapy available for patients with MoCD. We demonstrate efficient uptake of cPMP and restoration of molybdenum cofactor–dependent enzyme activities. Further neurodegeneration by toxic metabolites was stopped in the reported patient. We also demonstrated the feasibility to detect MoCD in newborn-screening cards to enable early diagnosis.Keywords
This publication has 12 references indexed in Scilit:
- Molybdenum cofactors, enzymes and pathwaysNature, 2009
- Molybdenum cofactor deficiency: Clinical features in a Turkish patientBrain & Development, 2007
- Molybdenum cofactor biosynthesis and deficiencyCellular and Molecular Life Sciences, 2005
- Ten novel mutations in the molybdenum cofactor genes MOCS1 and MOCS2 and in vitro characterization of a MOCS2 mutation that abolishes the binding ability of molybdopterin synthaseHuman Genetics, 2005
- Rescue of lethal molybdenum cofactor deficiency by a biosynthetic precursor from Escherichia coliHuman Molecular Genetics, 2004
- The Tetrahydropyranopterin Structure of the Sulfur-free and Metal-free Molybdenum Cofactor PrecursorJournal of Biological Chemistry, 2004
- Mutations in the molybdenum cofactor biosynthetic genesMOCS1, MOCS2, andGEPHHuman Mutation, 2003
- Molybdenum cofactor-deficient mice resemble the phenotype of human patientsHuman Molecular Genetics, 2002
- Molybdenum cofactor deficiency associated with Dandy–Walker complexBrain & Development, 2001
- Genomic structure and mutational spectrum of the bicistronic MOCS1 gene defective in molybdenum cofactor deficiency type AHuman Genetics, 1998